Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hello
I ordered a pair for a raffle gift.. I wouldnt mind to see how the shoes that you received looks. Any way to see a pic please?
Thanks bud
Great to hear.. I ordered a pair for a raffle gift.. I wouldnt mind to see how the pair that you received looks. Any way to see a pic please?
Thanks bud
An ordinance that would allow alcohol delivery in the City of Lafayette was approved in a 8-1 vote at tonight's City-Parish Council meeting.
https://www.katc.com/news/local-news/lafayette-parish/lafayette-city-parish-council-approves-alcohol-delivery-ordinance-defers-vermilion-river-dredging-item
https://waitrapp.com/blog/alcohol-delivery-waitr-booze-cruise
The sticky of the "Transparency above all" had to go.
I guess there is such a thing as a stupid question?.. If you invested bc of Gullickson I feel bad for you. I invested bc of the brand, maeketing, increasing revenues, increasing margins close if not profitable this quarter (there is so much more good things. Too much to list). What I didnt invest in is something where management sells shares then goes silent until the price gets to where they want it.. Nobody would be dumping at 1.05 thats BS. If gullickson didnt walk they would never have updated the market with their highest revenue quarter yet.. (700K +/-50K is my guess)
The stock market is Predator (CEO MANAGEMENT AND LENDERS) and Prey (retail investors) and these guys are proving to be predators. Just like when Airware was the name.. I guess theyre too stupid to consider how fast a name spreads if they had shareholders to help? Im down over 65% and I consider end of year tax selloffs as a reason and dilution BUT there is PR they could/should have announced and looking prior to Aug31st shows a pattern of communication then after to suddenly stop. Three months they've been dogging the shareholder. I dont care if their margins are 60% and they broke even.. I hit the ask twice in those 3 months and the ask dropped immediately. We will see what happens. I bet their friends (financiers) loan money at a dollar (less) and the management rewards themselves while the shareholder gets the knife!
Just stay away from this company. They have the history of DESTROYING THE SHAREHOLDERS
Question, Why would the company give the settlement of $219,460 of bona fide obligations the Company owed to certain of its creditors (FRIENDS/SELF) price equal to the lowest closing bid (.0034) price for the common stock for the twenty trading days immediately preceding the delivery of such tranche (Check the knockdown). At no time may Trillium beneficially own more than 9.99% (wonder why so much pumping to dump) of the Company’s outstanding common stock.
Just saying its Bold Crook activity
Lust4Life is at many of these stores listed
https://www.huffpost.com/entry/black-friday-cyber-monday-2019-deals-on-clothes-shoes-bags_l_5db5f57de4b079eb95a5bc35
I'll take another bite. Lowered my average .77. Holiday sales may be great?
Figure when US exchanges closed and a Long holiday weekend is there a massive short push. I get it hammer until Monday?
I called my Wife, sister and Mother all know of the L4L.. I bought in just now because of it. I will hang around to see what L4L designs come out now theyre getting a larger audience (retail investors)
Could GB Sciences turn a new leaf? I think in the coming months GB has a chance to re-establish the company as being honest and FRUGAL.. But doubtful.
7/17 GB Sciences Files Novel Patent Application For Chronic Pain Treatments Based On Proprietary Cannabis-Derived Formulations
https://www.prnewswire.com/news-releases/gb-sciences-files-novel-patent-application-for-chronic-pain-treatments-based-on-proprietary-cannabis-derived-formulations-300885219.html
10/31 GB Sciences Welcomes Esteemed Patent and Intellectual Property Attorney, Mr. Edmond DeFrank, to Its Board of Directors
https://www.prnewswire.com/news-releases/gb-sciences-welcomes-esteemed-patent-and-intellectual-property-attorney-mr-edmond-defrank-to-its-board-of-directors-300949485.html
GB Sciences retained the benefit of Wellcana Plus's 50% interest in intellectual property developed under the Master Research and Development Agreement.
That's the most important for GB. What I want to know..Lousiana is moving in a way where medical is slow to fire up. But they cancelled the 10% thc cap. That alone will sign a few rec users up. They are introducing gummies (who cares IMO) but strong ones are enticing and expensive. I cant remember off hand what else but its not exciting for the recreational consumer. So that being said, removing that cao will grow the program much faster But not fast enough.. But now with the 8mm earn outs What numbers does the program need to hit?
They want to allow for flower then thats a sure thing for "patients" will sign and complain there is no flower pushing sales to higher profit margin products but negative view of the program..
Sale went through. Im glad they retained the research and formulations interest. These guys just reset themselves. The Earn out.. Stupid.. Look at Lousianas licensed patients.. In 3 months its only 130. LA got very greedy and thought they could sell marijuana one prescription at a time for each dose. As of nov 4th there were over 3000 prescriptions but only 130 patients. So what does GB have to do? Market their products for Lousisana in order to get paid?
Either way they just "re-Upped"
Watching NBC and BB over the weekend and this morning. There is a lot more focus on electric and alternative fuel vehicles. Anyone like GKIT and their chance of a future?
Every PR has assurance that the owners (financiers) will fund GKIT until its able to fund itself.
What did you think?
The Q looked just as trash as the last. But I think that was expected. Some improvements but also cost of goods increase dont like, Someone more acquainted with the company should give an unbiased.
My unbiased is that I think buying now is because of the potential catalysts the company can make?
I found this, May have no relation than the stated but Monaco
https://finance.yahoo.com/news/cls-holdings-announces-dominick-monaco-113000106.html
appointment of Dominick Monaco as Director of Plant Operations at City Trees, the Company’s branded products and bulk flower subsidiary. CLSH PLNH
Drug Discovery and Development of Novel Cannabis-Based Therapies
Through its wholly-owned, Canadian subsidiary, GBS Global Biopharma, Inc. (GBSGB), the Company has conducted ground-breaking research embracing the complexity of the whole plant led by Dr. Andrea Small-Howard, the Company’s Chief Science Officer, and Dr. Helen Turner, Vice President of Innovation and Dean of the Science and Technology Department at Chaminade University. Small-Howard and Turner posited that complex mixtures of cannabinoids and terpenes that are derived from native mixtures in the cannabis plant, but with precise optimizations, would provide more targeted and effective treatments for specific disease conditions than either single cannabinoids or whole plant formulations. They developed a rapid screening and assaying system which tested thousands of combinations of cannabinoids and terpenes in vitro against cell-based models of disease. This process identified precise mixtures of cannabinoids and terpenes, many of which contained no THC, to treat categories of disease conditions, including neurological disorders, inflammation, heart disease, metabolic syndrome, chronic and neuropathic pain.
GBSGB’s drug discovery process combines: 1) HTS: high throughput screening of tens of thousands of combinations of compounds derived from specific chemovars of the cannabis plant in well-established cellular models of diseases, and 2) NPP: a proprietary Network Pharmacology Platform algorithm for the prediction of complex therapeutic mixtures that the Company spent two-and-a-half-years training and testing against cell assay data. This combined approach to drug discovery increases research efficiency and accuracy reducing the time from ideation to patenting from 7 years to 1.5 years. Screening of cannabis-based mixtures for drug discovery involves the testing of specific combinations of plant chemicals from many naturally occurring cannabis chemovars and the use of live models for these diseases that have been well established by other researchers. First, the Company finds chemovars that show some therapeutic activity, and then refines these natural mixtures to optimize their effectiveness in cellular assays by removing compounds that do not act synergistically with the others in the mixtures. The Company also use its internally-validated Network Pharmacology Platform to prioritize and eliminate some potential combinations, which reduces the time in the discovery period.
The U.S. Patent and Trademark Office allows complex mixtures to be claimed as Active Pharmaceutical Ingredients, and GBSGB has a series of patents containing cannabis-derived complex mixtures that act as therapeutic agents for specific disease categories, as described below. GBSGB’s patents are protected whether the individual compounds are derived from the cannabis plant, another plant, synthetically produced, or derived from a combination of sources for the individual chemical compounds in these mixtures.
GBS Global Biopharma, Inc. has made significant strides in the past year with respect to both discovery research and product development programs. Both lead Rx programs in Parkinson’s disease and chronic neuropathic pain are now in preclinical animal studies with Dr. Lee Ellis of the NRC in Halifax. For chronic neuropathic pain, GBSGB is testing its Myrcene-Containing Complex Mixtures (MCCM) both as encapsulated, time-released nanoparticles, as well as in non-encapsulated forms of these therapeutic mixtures. For Parkinson’s disease, the initial clinical prototypes of GBSGB Cannabinoid-Containing Complex Mixtures (CCCM) are being formulated by Catalent Pharma using Catalent’s Zydis® Orally Disintegrating Tablet technology. Catalent has reported that the prototypes passed the initial Feasibility Testing Phase, and Catalent is now working on the Proof of Concept Study with our GBS101.PD, GBS102.PD, and GBS103.PD formulations. Three new patent applications were filed, two new patent applications are being prepared for filings, and we have licensed another patented delivery method, oral thin films. We are also raising awareness of our work through six peer-reviewed journal articles and a dozen presentations at national and international meetings. Favorable Research Updates from our university collaborators reveal the promise in our discovery programs with Michigan State University (HIV-Associated Neurodegenerative Disorder), Chaminade University (Neuropathic Pain, Metabolic Syndrome), the University of Athens, Greece (Cannabis Metabolomics), and the University of Seville, Spain (Time-Released Nanoparticles). The University of Seville has
completed functional testing on nanoparticles containing myrcene, nerolidol, and beta-caryophyllene. In these cell-based assays, the effectiveness and kinetics of the nanoparticle-forms of these terpenes were compared with the “naked” terpenes both individually and in mixtures. In all cases, the effectiveness of the nanoparticles were superior to the naked terpenes, however, the mixtures were dramatically more effective than the individuals. These results from Seville are very promising as these nanoparticles are now entering the animal testing phase at the NRC in Halifax.
Where was this promoted? I hadnt seen any article.
Anyone else here Publix is picking Nightfood up in Jan 2020?
Harris teeter is same region
https://www.bloomberg.com/press-releases/2019-10-08/nightfood-announces-distribution-in-harris-teeter-supermarkets-adding-over-250-stores-throughout-the-southeast-and-mid-atlantic
I think GB might have something ahead for that 8mm. Could there be Gov contract?
Yea I remember reading they think there is 3-4 strong candidates
Im going to tell the reader right now. There is No profitability with the Louisiana operations.
xpected to close by the end of October 2019, the sale is for $16 million to GB Sciences, $7 million in cash at closing, $1 million in cash within 60 days of closing, and the remaining $8 million as an earn out. The actual proceeds realized through the earn out and the timing of those proceeds will depend upon the profitability of the Louisiana operations.
Thats a very nice perk to that payment plan
Dont they have a drug trial for parkinsons? Animal
That was yesterday at 4. How the heck did you not see that? You know thats how the company been operating.. a good deal for funding.
If something significant is to be announced in the next week then a lot of us had our shares stolen!
Go after the tired parent with monsters running around close to bedtime. Get the consumer young so their taste is developed to Nightfood. Instead of converting the sugar junkies.
Smaller than a pint? You mean a box with bars in them? Smaller than a pint is a waste of money to package, for a scoop of ice cream?
Something is going on
So is the DEA bid still ongoing or had it been closed? What are they doing with the board?
You sound pretty informed but arent they doing research for the DEA?
Their lab seems decent, what could happen?
Would like to hear about what theyre doing in the lab. What is Andrea Howard working on? There must be something private party offered besides chump change for the license?
With so much of the float short yesterday no wonder no one mentioned waitr along with Grubhub. Huge squeeze
I think patience will really pay off here. A lot of shorts trying to cover, algorithms selling in to the pressure right out of the gates. Board and CFO will keep Waitr in a slump until in compliance. Compared to Waitr competitors Waitr is very undervalued
Yes Grubhub following suit. WTRH, one would think is working aggressively to show some improvement, Price said improvement was immediate.. Expectations low, positive looking Q.. Seasonal Q2 similar Q3 But Q4 is when business picks up.